Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China

被引：0
|
作者：
Lifeng Mu
Benhong Zhou
机构：
[1] Renmin Hospital of Wuhan University,Department of Pharmacy
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Alectinib; China; Cost-effectiveness; Non-small-cell lung cancer; Oncology; Survival extrapolation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：968 / 970
页数：2
相关论文
共 50 条
  • [41] Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
    Watanabe, Satoshi
    Sakai, Kazuko
    Matsumoto, Naoya
    Koshio, Jun
    Ishida, Akira
    Abe, Tetsuya
    Ishikawa, Daisuke
    Tanaka, Tomohiro
    Aoki, Ami
    Kajiwara, Tomosue
    Koyama, Kenichi
    Miura, Satoru
    Goto, Yuka
    Sekiya, Tomoki
    Suzuki, Ryo
    Kushiro, Kohei
    Fujisaki, Toshiya
    Yanagimura, Naohiro
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Saida, Yu
    Yoshizawa, Hirohisa
    Nishio, Kazuto
    Kikuchi, Toshiaki
    CANCERS, 2023, 15 (01)
  • [42] Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer
    Chai, Q.
    Gu, C.
    Zhang, Y. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S738 - S738
  • [43] Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis
    Wang, Lida
    Sheng, Zhixin
    Zhang, Junying
    Song, Jiwu
    Teng, Lili
    Liu, Liping
    Li, Qianpeng
    Wang, Baohong
    Li, Bin
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (02) : 87 - 96
  • [44] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [45] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    PLOS ONE, 2018, 13 (10):
  • [46] Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK plus advanced non-small-cell lung cancer in France
    Sivignon, Marine
    Monnier, Remi
    Tehard, Bertrand
    Roze, Stephane
    PLOS ONE, 2020, 15 (01):
  • [47] Cost-effectiveness of chemotherapy in non-small-cell lung cancer
    Saglam, S
    Yetis, B
    Ozyilkan, O
    Akçali, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3750 - 3751
  • [48] The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
    Dai, Zhanjing
    Xu, Jiayi
    Chang, Feng
    Zhou, Wanxin
    Ren, Ting
    Qiu, Jiaxin
    Lu, Yun
    Lu, Yuqiong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [49] Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.
    Kang, Jin
    Zhang, Xuchao
    Chen, Huajun
    Zhou, Qing
    Tu, Haiyan
    Li, Wen-Feng
    Wu, Yi-Long
    Yang, Jinji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer
    Jahanzeb, Mohammad
    Lin, Huamao M.
    Pan, Xiaoyun
    Yin, Yu
    Baumann, Pia
    Langer, Corey J.
    CLINICAL LUNG CANCER, 2021, 22 (01) : 49 - 57
12345